NYSE Euronext Announces Trading Volumes for December 2012 and Other Metrics

  NYSE Euronext Announces Trading Volumes for December 2012 and Other Metrics

Global Derivatives ADV of 7.5 Million Contracts in December In-line with Prior
                                     Year
        NYSE Liffe Fixed Income Products ADV Up 17% Versus Prior Year
                  European and U.S. Cash Equities ADV Lower

Business Wire

NEW YORK -- January 10, 2013

NYSE Euronext (NYX) today announced trading volumes for its global derivatives
and cash equities exchanges for December 2012^1. Global derivatives average
daily volume (“ADV”) of 7.5 million contracts in December 2012 was down
slightly compared to December 2011 and decreased 8.0% from November 2012
levels on seasonally slower trading activity. European derivatives fixed
income ADV, however, increased 17.4% from December 2011 levels. Trading
volumes in European and U.S. equities, declined both year-over-year and
month-over-month.

Highlights

  *NYSE Euronext global derivatives ADV in December 2012 of 7.5 million
    contracts decreased 0.2% compared to December 2011, and decreased 8.0%
    from November 2012 levels.
  *NYSE Euronext European derivatives products ADV in December 2012 of 3.5
    million contracts increased 1.5% compared to December 2011, but decreased
    12.4% from November 2012 levels. Excluding Bclear, NYSE Liffe's trade
    administration and clearing service for OTC products, European derivatives
    products ADV increased 8.5% compared to December 2011 and increased 1.5%
    from November 2012.
  *NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex Options) ADV of
    3.9 million contracts in December 2012 decreased 1.2% compared to December
    2011 levels, and decreased by 4.4% from November 2012 levels. NYSE
    Euronext’s U.S. options exchanges accounted for 27.2% of total U.S.
    consolidated equity options trading in December 2012, down from 27.7% in
    December 2011 and down from 28.1% in November 2012.
  *NYSE Liffe U.S. ADV of approximately 72,600 contracts decreased from
    89,600 contracts in December 2011, but increased from 51,500 contracts in
    November 2012.
  *NYSE Euronext European cash products ADV of 1.1 million transactions in
    December 2012 decreased 20.2% compared to December 2011 and decreased 8.7%
    compared to November 2012.
  *NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE-MKT) handled
    ADV of 1.5 billion shares in December 2012 decreased 14.7% compared to
    December 2011 and decreased 3.4% compared to November 2012. NYSE
    Euronext’s Tape A matched market share in December 2012 was 31.9%, down
    from 33.4% in December 2011, but up from 31.7% in November 2012.
  *The preliminary average net revenue per transaction type (as defined
    below) for each of the primary trading venues in the fourth quarter of
    2012 is included below:


                                                          Preliminary
Trading Venue                           4Q11     3Q12     4Q12
European Derivatives (ex. Bclear)^1         $0.698     $0.657     $0.67
U.S. Derivatives^2                          $0.148     $0.144     $0.14
European Cash^3                             $0.582     $0.537     $0.58
U.S. Cash^4                             $0.039   $0.040   $0.040

^1 Average net revenue per contract, excluding Bclear.
^2 Average net revenue per contract. Excludes NYSE Liffe U.S. trading volume.
^3 Average net revenue per transaction.
^4 Average net revenue per 100 shares handled.


Derivatives Trading

European Derivatives

  *NYSE Euronext European derivatives products ADV in December 2012 was 3.5
    million futures and options contracts, an increase of 1.5% from December
    2011, but a decrease of 12.4% from November 2012.
  *The 3.5 million in European derivatives futures and options contracts ADV
    in December 2012 consisted of 2.4 million contracts executed through our
    full-service LIFFE CONNECT trading platform and 1.1 million contracts, or
    31.6%, executed through Bclear, NYSE Liffe's trade administration and
    clearing service for OTC products. Excluding Bclear, European derivatives
    products ADV increased 8.5% compared to December 2011 and increased 1.5%
    from November 2012.
  *In the fourth quarter of 2012, European derivatives products ADV of 3.5
    million contracts was 2.3% below prior year levels. The 3.5 million in
    futures and options contracts ADV in the fourth quarter of 2012 consisted
    of 2.3 million contracts executed through LIFFE CONNECT trading platform
    and 1.2 million contracts, or 33.7%, executed through Bclear.
  *For the full-year 2012, European derivatives products ADV of 3.7 million
    contracts was 16.8% below prior year levels. The 3.7 million in futures
    and options contracts ADV year-to-date consisted of 2.6 million contracts
    executed through LIFFE CONNECT trading platform and 1.1 million contracts,
    or 29.7%, executed through Bclear.
  *Total fixed income products ADV of 1.6 million contracts in December 2012
    increased 17.4% from December 2011 and increased 0.3% from November 2012.
    In the fourth quarter of 2012, total fixed income products ADV of 1.6
    million contracts was 13.3% below prior year levels. For the full-year
    2012, total fixed income products ADV of 1.8 million contracts was 22.0%
    below prior year levels.
  *Total equity products (including Bclear) ADV of 1.8 million contracts in
    December 2012 decreased 10.6% compared to December 2011 and decreased
    21.9% from November 2012. The 1.8 million contracts in equity products ADV
    consisted of 1.3 million contracts in individual equity products ADV and
    0.5 million contracts in equity index products ADV. The 1.3 million
    contracts in individual equity products ADV consisted of 0.9 million in
    futures contracts, which represented a 14.0% decrease compared to December
    2011 and 0.4 million in options contracts, which represented a 17.9%
    decrease compared to December 2011. In the fourth quarter of 2012, total
    equity products ADV of 1.9 million contracts were 7.6% below prior year
    levels. For the full-year 2012, total equity products ADV of 1.9 million
    contracts were 12.3% below prior year levels.
  *Total commodities products ADV of 97,000 contracts in December 2012
    increased 43.3% compared to December 2011 and increased 12.5% compared to
    November 2012. In the fourth quarter of 2012, total commodities product
    ADV of 96,500 contracts was 34.3% above prior year levels. For the
    full-year 2012, total commodities product ADV of 89,000 contracts was
    10.6% above prior year levels.

U.S. Derivatives

  *NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex Options) ADV of
    3.9 million contracts in December 2012 decreased 1.2% compared to December
    2011 and decreased 4.4% compared to November 2012. In the fourth quarter
    of 2012, U.S. equity options ADV of 4.0 million contracts was 6.7% below
    prior year levels. For the full-year 2012, U.S. equity options ADV of 3.9
    million contracts was 11.6% below prior year levels.
  *Total U.S. consolidated equity options ADV increased 0.4% to 14.3 million
    contracts in December 2012 compared to December 2011, but decreased 1.5%
    compared to November 2012. In the fourth quarter of 2012, U.S.
    consolidated equity options ADV of 14.3 million contracts was 7.6% below
    prior year levels. For the full-year 2012, U.S. consolidated equity
    options ADV of 14.7 million contracts was 12.2% below prior year levels.
  *NYSE Euronext’s U.S. options exchanges accounted for 27.2% of the total
    U.S. consolidated equity options trading in December 2012, down from 27.7%
    in December 2011 and down slightly from a record 28.1% in November 2012.
  *NYSE Liffe U.S. ADV of approximately 72,600 contracts decreased from
    89,600 contracts in December 2011, but increased from 51,500 contracts in
    November 2012. In December 2012, the mini MSCI Index futures traded a
    record ADV of 41,570 contracts, an increase of 108% compared to December
    2011, and open interest across the entire MSCI complex hit an all time
    high on December 19, 2012 of 267,932 contracts. In the fourth quarter of
    2012, U.S. futures and futures options ADV of 55,200 contracts was 39.4%
    below prior year levels. For the full-year 2012, U.S. futures and futures
    options ADV of 72,700 contracts was 10.4% below prior year levels.

Cash Trading

European Cash

  *NYSE Euronext European cash products ADV of 1.1 million transactions in
    December 2012 decreased 20.2% compared to December 2011 and decreased 8.7%
    compared to November 2012.
  *NYSE Euronext market share in European Cash products in December 2012 was
    68.7%, up from 66.0% in December 2011 and up from 64.9% in November 2012.
  *In the fourth quarter of 2012, European cash products market share was
    66.5% with ADV of 1.2 million transactions which was 25.6% below prior
    year levels.
  *For the full-year 2012, European cash products market share was 66.2% with
    ADV of 1.4 million transactions which was 15.5% below prior year levels.

U.S. Cash

  *NYSE Euronext U.S. cash products handled ADV in December 2012 decreased
    14.7% to 1.5 billion shares compared to December 2011 and decreased 3.4%
    from November 2012.
  *In the fourth quarter of 2012, U.S. cash products handled ADV was 1.6
    billion shares, down 27.3% from prior year levels.
  *For the full-year 2012, U.S. cash products handled ADV was 1.7 billion
    shares, down 26.2% from prior year levels.
  *NYSE Euronext’s Tape A matched market share in December 2012 was 31.9%,
    down from 33.4% in December 2011, but up from 31.7% in November 2012.

Exchange Traded Funds

  *NYSE Euronext U.S. matched exchange-traded funds ADV (included in volumes
    for Tape B and Tape C) of 193 million shares in December 2012 decreased
    22.1% compared to December 2011 and decreased 7.5% compared to November
    2012.
  *In the fourth quarter of 2012, NYSE Euronext U.S. matched exchange-traded
    funds ADV of 197 million shares was 38.9% below prior year levels.
  *For the full-year 2012, NYSE Euronext U.S. matched exchange-traded funds
    ADV of 211 million shares was 34.9% below prior year levels.

Other Metrics

  *On October 5, 2012, NYSE Euronext closed on the public offering of $850
    million 2.00% notes due in October 2017. The proceeds from this offering
    were used to fund the purchase of $336 million of our outstanding $750
    million 4.80% notes due in June 2013 and €80 million of our €1 billion
    5.375% notes due in June 2015 and for other general corporate purposes,
    including the reduction in outstanding commercial paper. As a result of
    the refinancing, interest expense is expected to decline by approximately
    $1 million in the fourth quarter of 2012, excluding a $24 million one-time
    charge for the refinancing which will be excluded from fourth quarter 2012
    non-GAAP financial results. The refinancing is expected to save an
    annualized $15 million and $24 million in interest expense in 2013 and
    2014, respectively.
  *The average EUR/USD exchange rate for the fourth quarter of 2012 of $1.30
    represented an increase of 3.7% from the third quarter of 2012 and a
    decrease of 3.8% compared to the fourth quarter of 2011. The average
    GBP/USD exchange rate for the fourth quarter of 2012 of $1.61 represented
    an increase of 1.6% from the third quarter of 2012 and an increase of 2.1%
    compared to the fourth quarter of 2011.
  *During the fourth quarter of 2012, a total of 1.1 million shares were
    repurchased at an average price of $24.67. As a result of these
    repurchases, the weighted average diluted shares outstanding in the fourth
    quarter of 2012 was 245 million shares.

Please click here for the Monthly Transaction Activity Data Table.

About NYSE Euronext

NYSE Euronext (NYX) is a leading global operator of financial markets and
provider of innovative trading technologies. The company's exchanges in Europe
and the United States trade equities, futures, options, fixed-income and
exchange-traded products. With approximately 8,000 listed issues (excluding
European Structured Products), NYSE Euronext's equities markets - the New York
Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca -
represent one-third of the world’s equities trading, the most liquidity of any
global exchange group. NYSE Euronext also operates NYSE Liffe, one of the
leading European derivatives businesses and the world's second-largest
derivatives business by value of trading. The company offers comprehensive
commercial technology, connectivity and market data products and services
through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more
information, please visit: http://www.nyx.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. In some cases, you can identify forward-looking statements by words such
as “may,” “hope,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,”
“believe,” “estimate,” “predict,” “potential,” “continue,” “could,” “future”
or the negative of those terms or other words of similar meaning. You should
carefully read forward-looking statements, including statements that contain
these words, because they discuss our future expectations or state other
“forward-looking” information. Forward-looking statements involve a number of
risks and uncertainties. ICE and NYSE Euronext caution readers that any
forward-looking statement is not a guarantee of future performance and that
actual results could differ materially from those contained in the
forward-looking statement. Such forward-looking statements include, but are
not limited to, statements about the benefits of the proposed merger involving
ICE and NYSE Euronext, including future financial results, ICE’s and NYSE
Euronext’s plans, objectives, expectations and intentions, the expected timing
of completion of the transaction and other statements that are not historical
facts. Important factors that could cause actual results to differ materially
from those indicated by such forward-looking statements are set forth in ICE’s
and NYSE Euronext’s filings with the U.S. Securities and Exchange Commission
(the “SEC”). These risks and uncertainties include, without limitation, the
following: the inability to close the merger in a timely manner; the inability
to complete the merger due to the failure of NYSE Euronext stockholders to
adopt the merger agreement or the failure of ICE stockholders to approve the
issuance of ICE common stock in connection with the merger; the failure to
satisfy other conditions to completion of the merger, including receipt of
required regulatory and other approvals; the failure of the proposed
transaction to close for any other reason; the possibility that any of the
anticipated benefits of the proposed transaction will not be realized; the
risk that integration of NYSE Euronext’s operations with those of ICE will be
materially delayed or will be more costly or difficult than expected; the
challenges of integrating and retaining key employees; the effect of the
announcement of the transaction on ICE’s, NYSE Euronext’s or the combined
company’s respective business relationships, operating results and business
generally; the possibility that the anticipated synergies and cost savings of
the merger will not be realized, or will not be realized within the expected
time period; the possibility that the merger may be more expensive to complete
than anticipated, including as a result of unexpected factors or events;
diversion of management’s attention from ongoing business operations and
opportunities; general competitive, economic, political and market conditions
and fluctuations; actions taken or conditions imposed by the United States and
foreign governments and regulatory authorities; and adverse outcomes of
pending or threatened litigation or government investigations. In addition,
you should carefully consider the risks and uncertainties and other factors
that may affect future results of the combined company described in the
section entitled “Risk Factors” in the joint proxy statement/prospectus to be
delivered to ICE’s and NYSE Euronext’s respective shareholders, and in ICE’s
and NYSE Euronext’s respective filings with the SEC that are available on the
SEC’s web site located at www.sec.gov, including the sections entitled “Risk
Factors” in ICE’s Form 10−K for the fiscal year ended December 31, 2011, as
filed with the SEC on February 8, 2012, and ICE's Quarterly Reports on Form
10-Q for the quarters ended June 30, 2012, as filed with the SEC on August 1,
2012 and September 30, 2012, as filed with the SEC on November 5, 2012, and
“Risk Factors” in NYSE Euronext’s Form 10−K for the fiscal year ended December
31, 2011, as filed with the SEC on February 29, 2012. You should not place
undue reliance on forward-looking statements, which speak only as of the date
of this press release. Except for any obligations to disclose material
information under the Federal securities laws, NYSE Euronext undertakes no
obligation to publicly update any forward-looking statements to reflect events
or circumstances after the date of this press release.

Important Information About the Proposed Transaction and Where to Find It:

In connection with the proposed transaction, ICE intends to file with the SEC
a registration statement on Form S−4, which will include a joint proxy
statement/prospectus with respect to the proposed acquisition of NYSE
Euronext. The final joint proxy statement/prospectus will be delivered to the
stockholders of ICE and NYSE Euronext. Investors and security holders of both
ICE and NYSE Euronext are urged to read the joint proxy statement/prospectus
regarding the proposed transaction carefully and in its entirety, including
any documents previously filed with the SEC and incorporated by reference into
the joint proxy statement/prospectus, when it becomes available because it
will contain important information regarding ICE, NYSE Euronext and the
proposed merger. Investors will be able to obtain a free copy of the joint
proxy statement/prospectus, as well as other filings containing information
about ICE and NYSE Euronext, without charge, at the SEC’s website at
http://www.sec.gov/. Investors may also obtain these documents, without
charge, from ICE’s website at http://www.theice.com.

Participants in the Merger Solicitation:

ICE, NYSE Euronext and their respective directors, executive officers and
other members of management and employees may be deemed to be participants in
the solicitation of proxies in respect of the transactions contemplated by the
merger agreement.

You can find information about ICE and ICE’s directors and executive officers
in ICE’s Annual Report on Form 10-K for the year ended December 31, 2011, as
filed with the SEC on February 8, 2012, and ICE’s proxy statement for its 2012
annual meeting of stockholders, as filed with the SEC on March 30, 2012.

You can find information about NYSE Euronext and NYSE Euronext’s directors and
executive officers in NYSE Euronext’s Annual Report on Form 10-K for the year
ended December 31, 2011, as filed with the SEC on February 29, 2012, and NYSE
Euronext’s proxy statement for its 2012 annual meeting of stockholders, filed
with the SEC on March 26, 2012.

Additional information about the interests of potential participants will be
included in the joint proxy statement/prospectuses, if and when it becomes
available, and the other relevant documents filed by ICE and NYSE Euronext
with the SEC.

This announcement does not constitute and offer or any solicitation of any
offer, to buy or subscribe for any securities.

^1 All NYSE Euronext derivatives transactions count buy and sell orders
together as a single transaction. NYSE Euronext European equities transactions
count each buy and sell order as separate transactions, NYSE Euronext U.S.
equities transactions count buy and sell orders together as a single
transaction.


NYSE Euronext
Monthly Volume Summary
                   
                        Average Daily Volume            Total Volume                      Average Daily        Total Volume
                                                                                              Volume
                                                                                                         % Chg                     % Chg
(Unaudited;                                                                                   YTD        vs.                       vs.
contracts in            Dec-12   Dec-11   % Chg       Dec-12    Dec-11    % Chg       2012                 YTD 2012   
thousands)                                                                                               YTD                       YTD
                                                                                                         2011                      2011
                                                                                                                                   
Number of
Trading Days -          19         21                     19          21                      256                    256
European Cash
Number of
Trading Days -          19         21                     19          21                      257                    257
European
Derivatives
Number of
Trading Days -          20         21                     20          21                      250                    250
U.S. Markets
                                                                                                                                   
European
Derivatives             3,491      3,440      1.5%        66,326      72,245      -8.2%       3,719      -16.8%      955,802       -16.8%
Products
of which Bclear         1,103      1,240      -11.1%      20,949      26,046      -19.6%      1,103      -3.3%       283,554       -3.3%
                                                                                                                                   
Total Fixed             1,587      1,352      17.4%       30,146      28,390      6.2%        1,754      -22.0%      450,896       -22.0%
Income Products
                                                                                                                                   
Short Term
Interest Rate           1,468      1,268      15.8%       27,897      26,625      4.8%        1,602      -24.1%      411,806       -24.1%
Products
Medium and Long
Term Interest           118        84         40.8%       2,249       1,766       27.4%       152        9.5%        39,089        9.5%
Rate Products ^
1
                                                                                                                                   
Total Equity            1,807      2,021      -10.6%      34,335      42,432      -19.1%      1,875      -12.3%      481,969       -12.3%
Products ^ 2
                                                                                                                                   
Individual              1,296      1,529      -15.2%      24,626      32,109      -23.3%      1,398      -10.4%      359,382       -10.4%
Equity Products
Futures                 907        1,056      -14.0%      17,241      22,168      -22.2%      959        -1.6%       246,542       -1.6%
Options                 389        473        -17.9%      7,385       9,941       -25.7%      439        -25.1%      112,841       -25.1%
Equity Index            511        492        3.9%        9,709       10,323      -6.0%       477        -17.5%      122,587       -17.5%
Products
                                                                                                                                   
of which Bclear         1,103      1,240      -11.1%      20,949      26,046      -19.6%      1,103      -3.3%       283,554       -3.3%
Individual              983        1,142      -14.0%      18,671      23,986      -22.2%      1,027      -3.1%       263,840       -3.1%
Equity Products
Futures                 907        1,055      -14.0%      17,241      22,165      -22.2%      938        -2.2%       240,967       -2.2%
Options                 75         87         -13.2%      1,430       1,820       -21.4%      89         -11.9%      22,873        -11.9%
Equity Index            120        98         22.2%       2,278       2,060       10.6%       77         -5.5%       19,714        -5.5%
Products
                                                                                                                                   
Commodity               97         68         43.3%       1,844       1,422       29.7%       89         10.6%       22,937        10.6%
Products
                                                                                                                                   
U.S.
Derivatives
Products
                                                                                                                                   
Equity Options
^ 3
                                                                                                                                   
NYSE Euronext
Options                 3,888      3,936      -1.2%       77,767      82,656      -5.9%       3,893      -11.6%      973,140       -12.3%
Contracts
Total
Consolidated            14,275     14,224     0.4%        285,492     298,702     -4.4%       14,727     -12.2%      3,681,821     -12.8%
Options
Contracts
                                                                                                                                   
NYSE Group              27.2%      27.7%                  27.2%       27.7%                   26.4%      0.1%        26.4%         0.1%
Share of Total
                                                                                                                                   
NYSE Liffe U.S.
                                                                                                                                   
Futures and
Futures Options         72.6       89.6       -19.0%      1,452       1,882       -22.8%      72.7       -10.4%      18,769.2      -10.4%
Volume*
                                                                                                                                   
European Cash
Products                1,068      1,338      -20.2%      20,297      28,095      -27.8%      1,445      -15.5%      370,013       -15.9%
(trades in
thousands)
                                                                                                                                   
Equities                1,026      1,287      -20.2%      19,503      27,023      -27.8%      1,396      -15.1%      357,365       -15.4%
Exchange-Traded         12         15         -25.0%      221         325         -32.1%      13         -35.0%      3,412         -35.2%
Funds
Structured              24         31         -20.9%      459         642         -28.4%      31         -25.7%      7,885         -26.0%
Products
Bonds                   6          5          20.5%       114         104         9.0%        5          5.8%        1,350         5.3%
                                                                                                                                   
U.S. Cash
Products                1,531      1,794      -14.7%      30,623      37,682      -18.7%      1,685      -26.2%      421,338       -26.8%
(shares in
millions) ^ 5
                                                                                                                                   
NYSE Listed
(Tape A) Issues
^4
                                                                                                                                   
Handled Volume          1,110      1,277      -13.1%      22,196      26,821      -17.2%      1,207      -24.9%      301,769       -25.5%
^5
Matched Volume          1,068      1,212      -11.8%      21,363      25,445      -16.0%      1,147      -24.7%      286,785       -25.3%
^6
Total NYSE
Listed                  3,353      3,623      -7.4%       67,069      76,086      -11.9%      3,659      -16.3%      914,654       -16.9%
Consolidated
Volume
                                                                                                                                   
Share of Total
Consolidated
Volume
Handled Volume          33.1%      35.3%      -2.2%       33.1%       35.3%       -2.2%       33.0%      -3.8%       33.0%         -3.8%
^5
Matched Volume          31.9%      33.4%      -1.5%       31.9%       33.4%       -1.5%       31.4%      -3.5%       31.4%         -3.5%
^6
                                                                                                                                   
NYSE Arca, MKT
and Regional
(Tape B) Listed
Issues
                                                                                                                                   
Handled Volume          225        295        -23.7%      4,501       6,192       -27.3%      248        -35.0%      61,957        -35.5%
^5
Matched Volume          209        263        -20.6%      4,171       5,517       -24.4%      225        -34.6%      56,127        -35.1%
^6
Total NYSE Arca
& MKT Listed            970        1,170      -17.1%      19,403      24,580      -21.1%      1,055      -28.4%      263,832       -29.0%
Consolidated
Volume
                                                                                                                                   
Share of Total
Consolidated
Volume
Handled Volume          23.2%      25.2%      -2.0%       23.2%       25.2%       -2.0%       23.5%      -2.4%       23.5%         -2.4%
^5
Matched Volume          21.5%      22.4%      -0.9%       21.5%       22.4%       -0.9%       21.3%      -2.0%       21.3%         -2.0%
^6
                                                                                                                                   
Nasdaq Listed
(Tape C) Issues
                                                                                                                                   
Handled Volume          196        222        -11.7%      3,926       4,669       -15.9%      230        -21.8%      57,612        -22.4%
^5
Matched Volume          175        189        -7.5%       3,506       3,979       -11.9%      199        -21.6%      49,756        -22.2%
^6
Total Nasdaq
Listed                  1,689      1,615      4.6%        33,776      33,911      -0.4%       1,749      -13.5%      437,168       -14.2%
Consolidated
Volume
                                                                                                                                   
Share of Total
Consolidated
Volume
Handled Volume          11.6%      13.8%      -2.2%       11.6%       13.8%       -2.2%       13.2%      -1.4%       13.2%         -1.4%
^5
Matched Volume          10.4%      11.7%      -1.3%       10.4%       11.7%       -1.3%       11.4%      -1.2%       11.4%         -1.2%
^6
                                                                                                                                   
Exchange-Traded
Funds ^5,7
                                                                                                                                   
Handled Volume          208        279        -25.3%      4,166       5,854       -28.8%      233        -35.4%      58,195        -35.9%
^5
Matched Volume          193        248        -22.1%      3,858       5,202       -25.8%      211        -34.9%      52,682        -35.5%
^6
Total ETF
Consolidated            929        1,139      -18.5%      18,575      23,917      -22.3%      1,020      -28.2%      255,004       -28.7%
Volume
                                                                                                                                   
Share of Total
Consolidated
Volume
Handled Volume          22.4%      24.5%      -2.1%       22.4%       24.5%       -2.1%       22.8%      -2.5%       22.8%         -2.5%
^5
Matched Volume          20.8%      21.7%      -0.9%       20.8%       21.7%       -0.9%       20.7%      -2.1%       20.7%         -2.1%
^6


^1  Data includes currency products.
^2   Includes all trading activities for Bclear, NYSE Liffe's clearing service
     for wholesale derivatives.
^3   Includes trading in U.S. equity options contracts, not equity-index
     options.
^4   Includes all volume executed in NYSE Group crossing sessions.
     Represents the total number of shares of equity securities and ETFs
^5   internally matched on the NYSE Group's exchanges or routed to and
     executed at an external market center. NYSE Arca routing includes
     odd-lots.
^6   Represents the total number of shares of equity securities and ETFs
     executed on the NYSE Group's exchanges.
^7   Data included in previously identified categories.
^*   ADVs calculated with the appropriate number of NYSE Liffe U.S. trading
     days.
     Source: NYSE Euronext, Options Clearing Corporation and Consolidated Tape
     as reported for equity securities.
     All trading activity is single-counted, except European cash trading
     which is double counted to include both buys and sells.


nyx.com

Please follow us at:
Exchanges Blog
Facebook
LinkedIn
Twitter

Contact:

Media:
Amsterdam +31.20.550.4488
Lisbon +351.217.900.029
New York +1.212.656.2411
Brussels +32.2.509.1392
London +44.20.7379.2789
Paris +33.1.49.27.11.33
or
Investor Relations:
New York +1.212.656.5700
 
Press spacebar to pause and continue. Press esc to stop.